Verismo Therapeutics
Philadelphia, US · Founded 2020 · Delaware corporation · 2 known investors
Verismo is a biopharmaceutical company founded by the inventors of Kymriah, the first FDA-approved CAR T cell therapy, developing next-generation CAR T therapies using KIR receptor technology to address limitations in first-generation approaches.
Founders & leadership
Verismo Therapeutics was founded in 2020 by Bryan Kim.
BK
Bryan KimCo-Founder and CEO/President
GK
Gene KimExecutive
Board
JS
Jong Sun YoonBoard director
DG
Dong Gun KimBoard director
YG
Yang Gon JinBoard director
Investors · 2
Also in the syndicate · 1
HLB Innovation
Reported raises · per SEC filings
Form D private placements$63.2M disclosed across 3 rounds · 2021–2026
▶$28MraisedMay 2026 · 1 investors · Other Health CareRule 506(b)
▶$28MraisedMay 2026 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jong Sun YoonDirector
- Dong Gun KimDirector
- Yang Gon JinDirector
- Bryan B. KimExecutive Officer, Director
- Gene KimExecutive Officer
- Offering amount
- $28M
- Amount sold
- $28M
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$19.2MraisedJul 2023 · 7 investors · PharmaceuticalsRule 506(b)
▶$19.2MraisedJul 2023 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Bryan B. KimExecutive Officer, Director, Promoter
- Hyuk Joo JeeDirector
- Amount sold
- $19.2M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$16MraisedApr 2021 · 3 investors · PharmaceuticalsRule 506(b)
▶$16MraisedApr 2021 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Bryan B. KimExecutive Officer, Director, Promoter
- Offering amount
- $16M
- Amount sold
- $16M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Kyverna Therapeutics4 shared keywordsKyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.
Leucid3 shared keywordsLeucid Bio develops CAR-T cell therapies based on a proprietary Lateral CAR platform that redesigns the CAR structure to mimic the lateral signalling arrangement of natural immune receptors. The technology, derived from 20 years of research led by Dr John Maher at King's College London, aims to increase T-cell potency and durability while reducing toxicity.
MD Anderson Cancer Center3 shared keywordsUT MD Anderson is a cancer research and treatment center that provides patient care, conducts research, and offers education in cancer prevention and treatment. It is part of the University of Texas System and operates as a nonprofit medical institution.
Companies competing with Verismo Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Verismo Therapeutics Secures $28 Million to Advance KIR-CAR Trials Ahead of Key 2026 Data Readout - TipRanks.comtipranks.com · Apr 2026Frequently asked questions
- What does Verismo Therapeutics do?
- Verismo is a biopharmaceutical company founded by the inventors of Kymriah, the first FDA-approved CAR T cell therapy, developing next-generation CAR T therapies using KIR receptor technology to address limitations in first-generation approaches.
- Who founded Verismo Therapeutics?
- Verismo Therapeutics was founded by Bryan Kim in 2020.
- Who are Verismo Therapeutics's investors?
- Verismo Therapeutics's investors include BRV Capital Management.
- How much funding has Verismo Therapeutics raised?
- Verismo Therapeutics has disclosed $63.2M raised across 3 rounds.
- Where is Verismo Therapeutics headquartered?
- Verismo Therapeutics is headquartered in Philadelphia, US.